Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9629122 | 0.97 | — | — | |
| SCHEMBL4464194 | 0.88 | — | — | |
| SCHEMBL29027947 | 0.88 | — | — | |
| SCHEMBL7597797 | 0.84 | TSHR (0.38) | FDPS | |
| SCHEMBL7601029 | 0.84 | TSHR (0.38) | FDPS | |
| SCHEMBL5134653 | 0.84 | DNM1 (0.36) | — | |
| SCHEMBL7593376 | 0.84 | TSHR (0.38) | FDPS | |
| SCHEMBL28731336 | 0.77 | TSHR (0.31) | — | |
| SCHEMBL1678667 | 0.72 | — | — | |
| SCHEMBL3974451 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3862362-A2 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3845547-A1 | GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3546579-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-7176227-B2 | For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis | KUREHA CORPORATION (JP) | 2007-02-13 | — | — | US | disclosed |